Literature DB >> 23054641

The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients.

Xinju Zhang1, Tingting Hu, Zhiyuan Wu, Zhihua Kang, Weiwei Liu, Ming Guan.   

Abstract

The presence of JAK2 V617F is associated with an inherited JAK2 46/1 haplotype, a risk factor for myeloproliferative neoplasms (MPN) in Caucasian populations. Whether the JAK2 46/1 haplotype is also a risk factor in the Chinese population is unknown. We assessed for the JAK2 46/1 haplotype and JAK2 V617F mutation in 225 MPN patients and 226 controls using a tagged SNP rs12340895. The allele frequencies of the JAK2 46/1 haplotype were distinct among different subtypes of MPN patients. The allele frequency was significantly higher in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) than that in controls, with PV patients having the highest allele frequency (0.58, P = 6.00E-15). The distribution of rs12340895 genotypes in the JAK2 V617F mutated MPN patients was significantly different from that in controls (P = 1.67E-15). The percentage of GG genotype in controls was 2.2 %, but 31.0 % in JAK2 V617F-positive MPN patients. All the PV, ET, and PMF patients with the GG genotype also exhibited the V617F mutation. Compared to that of controls, the difference in genotype distribution in PV patients was the most significant (P = 4.83E-21), followed by ET (P = 2.07E-05) and PMF (P = 1.99E-04). Our results suggest that the JAK2 46/1 haplotype is a risk factor for MPN in the Chinese population, and patients with GG genotype in rs12340895 locus are susceptible to JAK2 V617F mutation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23054641     DOI: 10.1007/s12185-012-1169-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  22 in total

1.  JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia.

Authors:  H Andrikovics; S Nahajevszky; M Koszarska; N Meggyesi; A Bors; G Halm; S Lueff; N Lovas; Z Matrai; J Csomor; R Rasonyi; M Egyed; J Varkonyi; G Mikala; A Sipos; A Kozma; E Adam; S Fekete; T Masszi; A Tordai
Journal:  Leukemia       Date:  2010-09-02       Impact factor: 11.528

2.  Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis.

Authors:  P Guglielmelli; F Biamonte; A Spolverini; L Pieri; A Isgrò; E Antonioli; A Pancrazzi; A Bosi; G Barosi; A M Vannucchi
Journal:  Leukemia       Date:  2010-06-03       Impact factor: 11.528

3.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Ashot Harutyunyan; Roland Jäger; Tiina Berg; Bettina Gisslinger; Ingrid Pabinger; Heinz Gisslinger; Robert Kralovics
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

Review 4.  Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.

Authors:  Ayalew Tefferi; William Vainchenker
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

5.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

Review 6.  Targeting JAK2 in the therapy of myeloproliferative neoplasms.

Authors:  Mamatha M Reddy; Anagha Deshpande; Martin Sattler
Journal:  Expert Opin Ther Targets       Date:  2012-02-17       Impact factor: 6.902

Review 7.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

8.  Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.

Authors:  Ola Landgren; Lynn R Goldin; Sigurdur Y Kristinsson; Elin A Helgadottir; Jan Samuelsson; Magnus Björkholm
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

9.  A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

Authors:  Outi Kilpivaara; Semanti Mukherjee; Alison M Schram; Martha Wadleigh; Ann Mullally; Benjamin L Ebert; Adam Bass; Sachie Marubayashi; Adriana Heguy; Guillermo Garcia-Manero; Hagop Kantarjian; Kenneth Offit; Richard M Stone; D Gary Gilliland; Robert J Klein; Ross L Levine
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

10.  Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera.

Authors:  Zhiyuan Wu; Hong Yuan; Xinju Zhang; Weiwei Liu; Jinhua Xu; Wei Zhang; Ming Guan
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

View more
  8 in total

1.  Inherited predisposition to myeloproliferative neoplasms.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Ther Adv Hematol       Date:  2013-08

2.  JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients.

Authors:  Mayumi Tanaka; Toshiaki Yujiri; Shunsuke Ito; Naoko Okayama; Toru Takahashi; Kenji Shinohara; Yoichi Azuno; Ryouhei Nawata; Yuji Hinoda; Yukio Tanizawa
Journal:  Int J Hematol       Date:  2013-02-22       Impact factor: 2.490

3.  TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients.

Authors:  Masafumi Matsuguma; Toshiaki Yujiri; Kaoru Yamamoto; Yasuko Kajimura; Yoshihiro Tokunaga; Mayumi Tanaka; Yoshinori Tanaka; Yukinori Nakamura; Yukio Tanizawa
Journal:  Int J Hematol       Date:  2019-09-30       Impact factor: 2.490

4.  Genetic Characteristics of Polycythemia Vera and Essential Thrombocythemia in Korean Patients.

Authors:  Eun-Hyung Yoo; Kyung-Jin Park; Hong-Hee Won; Jun-Hee Park; Jong-Ho Park; Seung-Tae Lee; Hee-Jin Kim; Soo-Mee Bang; Hyun-Sook Chi; Chul Won Jung; Sun-Hee Kim; Hongseok Yun; Choong-Hyun Sun; Inho Park; Seungmook Lee; Clarence Lee; Barry Merriman; Raymond Luo; Eileen Hwee Hong Tan; Keun-Joon Park; Na-Kyung Yoo; Jason J Kang; Jong-Won Kim
Journal:  J Clin Lab Anal       Date:  2016-05-02       Impact factor: 2.352

5.  Genetic association between germline JAK2 polymorphisms and myeloproliferative neoplasms in Hong Kong Chinese population: a case-control study.

Authors:  Su Pin Koh; Shea Ping Yip; Kwok Kuen Lee; Chi Chung Chan; Sze Man Lau; Chi Shan Kho; Chi Kuen Lau; Shek Ying Lin; Yat Ming Lau; Lap Gate Wong; Ka Leung Au; Kit Fai Wong; Raymond W Chu; Pui Hung Yu; Eudora Y D Chow; Kate F S Leung; Wai Chiu Tsoi; Benjamin Y M Yung
Journal:  BMC Genet       Date:  2014-12-20       Impact factor: 2.797

6.  Distinct molecular abnormalities underlie unique clinical features of essential thrombocythemia in children.

Authors:  R Fu; D Liu; Z Cao; S Zhu; H Li; H Su; L Zhang; F Xue; X Liu; X Zhang; T Cheng; R Yang; L Zhang
Journal:  Leukemia       Date:  2015-06-29       Impact factor: 11.528

7.  The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia.

Authors:  Yee Yee Yap; Kian Boon Law; Jameela Sathar; Ngee Siang Lau; Ai Sim Goh; Teng Keat Chew; Soo Min Lim; Padmini Menon; Yong Khee Guan; Azlan Bin Husin; Lily Lee Lee Wong; Lee Ping Chew; Sinari Salleh; Kim Yen Goh; Kin Wah Leong; Sen Mui Tan; Tee Chuan Ong; Su Hong Lim; See Guan Toh; Xavier Sim Yoon Han; Syed Carlo Edmund; Jenq Tzong Tan; Kian Meng Chang
Journal:  Exp Hematol Oncol       Date:  2018-12-17

8.  Germline variations at JAK2, TERT, HBS1L-MYB and MECOM and the risk of myeloproliferative neoplasms in Taiwanese population.

Authors:  Yi-Hao Chiang; Yu-Cheng Chang; Huan-Chau Lin; Ling Huang; Chun-Chia Cheng; Wei-Ting Wang; Hung-I Cheng; Nai-Wen Su; Caleb Gon-Shen Chen; Johnson Lin; Yi-Fang Chang; Ming-Chih Chang; Ruey-Kuen Hsieh; Wen-Chien Chou; Ken-Hong Lim; Yuan-Yeh Kuo
Journal:  Oncotarget       Date:  2017-07-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.